DASH Trial: Testing Ceralasertib and Trastuzumab Deruxtecan
Phase 1
51
about 4.6 years
18+
23 sites in CA, FL, IL +8
What this study is about
Researchers are testing a treatment with ceralasertib (AZD6738) and trastuzumab deruxtecan in people with advanced solid tumors that have HER2 changes or protein. The goal is to find the best dose of this combination for safety, side effects, and effectiveness. The trial also compares how colorectal and gastroesophageal cancers respond to treatment with ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Trastuzumab Deruxtecan
- 2.Take Ceralasertib
- 3.Undergo Biopsy Procedure
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
trastuzumab deruxtecan
infusion
Primary: Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase), Incidence of adverse events (Dose escalation phase)
Secondary: Best overall response, Disease control rate, Duration of response, Immunogenicity, Objective response rate (ORR), Overall survival, PD markers, Pharmacokinetics
biopsy, diagnostic, imaging
Oncology